Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Sep 27;105(7):877-80.
doi: 10.1038/bjc.2011.351.

Use of HC2 to triage women with borderline and mild dyskaryosis in the UK

M Arbyn, J Roelens, P Martin-Hirsch, S Leeson, N Wentzensen
Editorial

Use of HC2 to triage women with borderline and mild dyskaryosis in the UK

M Arbyn et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion of women with ASCUS or borderline dyskaryosis (BD) that have a positive Hybrid Capture II test, derived from a previously published meta-analysis completed with data from the UK Pilot Study. The consistency index I2 expresses the proportion of total variation due to inter-study heterogeneity; the P value corresponds with a χ2 test for inter-study heterogeneity.
Figure 2
Figure 2
Proportion of women with LSIL or mild dyskaryosis (MD) that have a positive Hybrid Capture II test, derived from a previously published meta-analysis completed with data from the UK Pilot Study.
Figure 3
Figure 3
Difference in high-risk HPV test positivity rate between LSIL/mild dyskaryosis (MD) and ASCUS/borderline dyskaryosis (BD) cases.
Figure 4
Figure 4
Absolute risk of underlying or incipient CIN2+ (left) or CIN3+ (right) in women with ASCUS or borderline dyskaryosis (BD) and LSIL or mild dyskaryosis (MD), according to the result of the HC2 HPV assay, derived from a meta-analysis (Arbyn et al, 2009, JCMM). Black: independent of HPV test=prevalence of disease; Blue: when hrHPV test is negative (=1-NPV); Red: when hrHPV test is positive (=PPV). Coloured lines contain the pooled mean and its 95% CI. For comparison the PPV of HC2 test observed in the British Pilot study (Kelly et al, 2011) are put at right (in purple) of the PPV from the meta-analysis.
See this image and copyright information in PMC

Comment on

References

    1. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J (2009) Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate. J Cell Mol Med 13: 648–659 - PMC - PubMed
    1. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J (2005) Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol 99(Suppl 3): 7–11 - PubMed
    1. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J (2006) Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(SUPPL. 3): S78–S89 - PubMed
    1. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M (2007) Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 197: 356. - PMC - PubMed
    1. Cuschieri K, Kitchener H, Horne AW, Busby-Earle C, Hardie A, Nelson L, Bailey A, Rowan J, Graham C, Cubie H (2010) Clinical Peformance of a broad-spectrum RNA assay in a high-prevalence disease setting. Montreal. 26th international Papillomavirus Conference & Clinical and Public Health Workshops 3–7

MeSH terms